Get 20% Off Journals at

Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis.

Ann Surg Oncol 2007 Feb 10;14(2):509-14. Epub 2006 Nov 10.

Département de Chirurgie Oncologique, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805, Villejuif, Cedex, France.

Background: Recently, the combination of complete cytoreductive surgery followed immediately by intraperitoneal chemotherapy achieved cure in some patients suffering from peritoneal carcinomatosis (PC). It is now well established that the prognostic impact of the completeness of cytoreduction is high. However, two different modes of intraperitoneal chemotherapy are proposed: early postoperative intraperitoneal chemotherapy (EPIC), which lasts for 5 days and is normothermic, and peroperative intraperitoneal chemohyperthermia (IPCH). To date, the results of these procedures have never been compared.

Aim Of The Study: To compare the complications and therapeutic results of EPIC and IPCH after complete cytoreductive surgery of colorectal PC.

Materials And Methods: Twenty-three consecutive patients with colorectal PC were selected based on the completeness of cytoreductive surgery and sufficient follow-up. They received IPCH with oxaliplatin (460 mg/m(2)) in 2 l/m(2) of dextrose, for 30 min at an intraperitoneal temperature of 43 degrees C, using the coliseum technique. We retrospectively carefully selected another 23 patients, for comparison purposes, suffering from the same disease, with characteristics as similar as possible, but treated earlier with EPIC (mitomycin C 10 mg/m(2) at day 0 and 5-FU 650 mg/m(2) from days 1 to 4), in 1 l/m(2) of ringer lactate. Data concerning these two groups were verified prospectively, but this study was a comparative historical analysis.

Results: The two groups were statistically comparable, except for the duration of surgery which was 68 min longer for the IPCH group. Mortality and morbidity were not significantly different, even if two deaths occurred in the EPIC group, and none in the IPCH group. However, the rate of digestive fistulas was higher (P = 0.02) in the EPIC group (26%) than in the IPCH group (0%). Overall survival (OS) was higher in the IPCH group, (54% at 5 years vs. 28% for EPIC), but not significantly (P = 0.22). Peritoneal carcinomatosis recurred much (P = 0.03) more frequently in the EPIC group (57%) than in the IPCH-group (26%).

Conclusion: This study provides strong arguments indicating that IPCH with oxaliplatin is better tolerated than EPIC with mitomycin C and 5-FU, and is twice as efficient in curing residual peritoneal carcinomatosis measuring less than 1 mm.

Download full-text PDF

Source Listing
February 2007
Save 15% Survey

Similar Publications

Castleman disease: A single-center case series.

Int J Surg Case Rep 2021 Feb 14;80:105650. Epub 2021 Feb 14.

Department of Surgery, University of Minnesota, Minneapolis, MN, USA; University of Minnesota Medical School, Minneapolis, MN, USA. Electronic address:

Background: Castleman disease (CD) is a rare lymphocytic disorder. Unicentric CD (UCD) has an excellent long-term prognosis after surgical excision; however, multicentric CD (MCD) has a severe clinical course with poor outcomes.

Study Design: We analyzed the clinical presentation of 28 patients treated at a single institution from 1995 to 2017. Read More

View Article and Full-Text PDF
February 2021

Two-step cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei with high peritoneal carcinomatosis index.

World J Surg Oncol 2021 Feb 23;19(1):60. Epub 2021 Feb 23.

Department of Surgery, Hôpital Maisonneuve-Rosemont, Université de Montréal, 5415 boul. de l'Assomption, Montréal, Québec, H1T 2M4, Canada.

Background: Complete cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is the only curative treatment for pseudomyxoma peritonei (PMP) arising from the appendix. High peritoneal carcinomatosis index (PCI) is associated with an increased risk of surgical complications. The objective of this study was to present the results of a planned two-step surgical strategy to decrease postoperative morbidity and improve resectability of patients with very high PCI. Read More

View Article and Full-Text PDF
February 2021

[Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer].

Chirurg 2021 Feb 23. Epub 2021 Feb 23.

Chirurgische Klinik Campus Charité Mitte | Campus Virchow Klinikum, Charité Universitätsmedizin, Berlin, Deutschland.

Background: Gastric cancer with peritoneal metastases is associated with an extremely poor prognosis. Developed multimodal treatment concepts, which include a combination of perioperative systemic treatment and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), show promising results with respect to improvement of the long-term survival.

Methods: This article contains a review of the literature of published studies on the topic of gastric cancer and peritoneal metastasis. Read More

View Article and Full-Text PDF
February 2021

Individual learning curve of cytoreductive surgery for peritoneal metastasis from colorectal cancer: A process with an impact on survival.

Eur J Surg Oncol 2021 Feb 16. Epub 2021 Feb 16.

Department of Surgical Oncology, Comprehensive Cancer Center Institut de Cancérologie de l'Ouest, Saint-Herblain, France.

Background: This study aimed to assess the learning curve (LC) of cytoredutive surgery (CRS) of peritoneal metastasis (PM) from colorectal cancer (CRC). Information about learning curves is important for developing teaching tools and well-structured training programs for the implementation of this complex procedure in new healthcare centers. The aim of this study was to estimate how many procedures an inexperienced surgeon must perform (the length of the learning period) in order to demonstrate an acceptably low rate of locoregional recurrence. Read More

View Article and Full-Text PDF
February 2021

Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Definitively Does not Deserve Its Bad Reputation.

Ann Surg Oncol 2021 Feb 20. Epub 2021 Feb 20.

Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France.

View Article and Full-Text PDF
February 2021